Delivering drugs to specific, hard-to-reach areas in the human body remains a challenge in drug development. Typically, drug molecules administered via pills or injections circulate randomly through ...
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...